Centessa Pharmaceuticals PLC
CNTA23.490USD
-0.050-0.21%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
3.16BCap. mercado
PérdidaP/E TTM
Más Datos de Centessa Pharmaceuticals PLC Compañía
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Información de Centessa Pharmaceuticals PLC
Símbolo de cotizaciónCNTA
Nombre de la empresaCentessa Pharmaceuticals PLC
Fecha de salida a bolsaMay 28, 2021
Director ejecutivoSaha (Saurabh)
Número de empleados77
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 28
Dirección3rd Floor
CiudadALTRINCHAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalWA14 2DT
Teléfono447391789784
Sitio Webhttps://www.centessa.com/
Símbolo de cotizaciónCNTA
Fecha de salida a bolsaMay 28, 2021
Director ejecutivoSaha (Saurabh)
Ejecutivos de Centessa Pharmaceuticals PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
77.08K
+16842.00%
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Mr. Iqbal Hussain
Mr. Iqbal Hussain
General Counsel and Chief Compliance Officer, Company Secretary
General Counsel and Chief Compliance Officer, Company Secretary
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Francesco de Rubertis, Ph.D.
Dr. Francesco de Rubertis, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Brett I. W. Zbar, M.D.
Dr. Brett I. W. Zbar, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Carol Stuckley
Ms. Carol Stuckley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
77.08K
+16842.00%
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Mr. Iqbal Hussain
Mr. Iqbal Hussain
General Counsel and Chief Compliance Officer, Company Secretary
General Counsel and Chief Compliance Officer, Company Secretary
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Francesco de Rubertis, Ph.D.
Dr. Francesco de Rubertis, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 18 de ene
Actualizado: dom., 18 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Medicxi Ventures (UK) LLP
13.67%
Avoro Capital Advisors LLC
7.40%
Adage Capital Management, L.P.
6.87%
Index Ventures SA
6.82%
General Atlantic LLC
5.04%
Otro
60.19%
Accionistas
Accionistas
Proporción
Medicxi Ventures (UK) LLP
13.67%
Avoro Capital Advisors LLC
7.40%
Adage Capital Management, L.P.
6.87%
Index Ventures SA
6.82%
General Atlantic LLC
5.04%
Otro
60.19%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
21.32%
Investment Advisor/Hedge Fund
20.31%
Hedge Fund
19.37%
Investment Advisor
16.87%
Private Equity
8.07%
Research Firm
1.42%
Individual Investor
0.61%
Bank and Trust
0.03%
Pension Fund
0.01%
Otro
12.00%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
239
133.92M
99.37%
+16.61K
2025Q3
241
133.90M
109.10%
+4.79M
2025Q2
226
132.04M
110.14%
-1.07M
2025Q1
214
132.76M
108.57%
-12.24M
2024Q4
180
128.06M
101.80%
+5.92M
2024Q3
158
122.07M
88.34%
+22.15M
2024Q2
135
99.90M
89.43%
+12.17M
2024Q1
129
87.74M
96.45%
-9.01M
2023Q4
114
84.27M
95.12%
+1.65M
2023Q3
113
82.62M
96.02%
+2.24M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Medicxi Ventures (UK) LLP
19.96M
13.67%
--
--
Sep 30, 2025
Avoro Capital Advisors LLC
10.81M
7.4%
+5.81M
+116.16%
Sep 30, 2025
Adage Capital Management, L.P.
10.04M
6.87%
+1.63M
+19.42%
Sep 30, 2025
Index Ventures SA
9.96M
6.82%
--
--
Sep 30, 2025
General Atlantic LLC
7.37M
5.04%
-2.31M
-23.91%
Nov 26, 2025
Fidelity Management & Research Company LLC
6.24M
4.27%
+2.41M
+63.08%
Sep 30, 2025
Janus Henderson Investors
5.41M
3.7%
-1.12M
-17.21%
Sep 30, 2025
T. Rowe Price Associates, Inc.
4.80M
3.29%
-1.10M
-18.69%
Sep 30, 2025
Farallon Capital Management, L.L.C.
4.33M
2.97%
-198.00K
-4.37%
Sep 30, 2025
First Light Asset Management, LLC
3.64M
2.49%
-657.60K
-15.32%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
3.56%
Virtus LifeSci Biotech Clinical Trials ETF
1.4%
Invesco Nasdaq Biotechnology ETF
0.23%
ProShares Ultra Nasdaq Biotechnology
0.23%
T Rowe Price Small-Mid Cap ETF
0.15%
iShares Biotechnology ETF
0.13%
Fidelity Fundamental Small-Mid Cap ETF
0.11%
iShares Intl Small Cap Equity Factor ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
SPDR S&P International Small Cap ETF
0%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción3.56%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.4%
Invesco Nasdaq Biotechnology ETF
Proporción0.23%
ProShares Ultra Nasdaq Biotechnology
Proporción0.23%
T Rowe Price Small-Mid Cap ETF
Proporción0.15%
iShares Biotechnology ETF
Proporción0.13%
Fidelity Fundamental Small-Mid Cap ETF
Proporción0.11%
iShares Intl Small Cap Equity Factor ETF
Proporción0.01%
Fidelity Nasdaq Composite Index ETF
Proporción0.01%
SPDR S&P International Small Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
